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The first large scale analysis of in vitro Absorption, Distribution, Metabolism, Excretion, 
and Toxicity (ADMET) data shared across multiple major Pharma has been performed. Using 
advanced matched molecular pair analysis (MMPA), we combined data from three 
pharmaceutical companies and generated ADMET rules, avoiding the need to disclose the 
full chemical structures. On top of the very large exchange of knowledge, all companies 
involved synergistically gained approximately 20% more rules from the shared 
transformations. There is good quantitative agreement between the rules based on shared data 
compared to both individual companies’ rules and rules published in the literature. Known 
correlations between logD, solubility, in vitro clearance and plasma protein binding also hold 
in transformation space, but there are also interesting exceptions. Data pools such as this 
allow focusing on particular functional groups and characterizing their ADMET profile. 
Finally the role of a corpus of robustly tested medicinal chemistry knowledge in the training 
of medicinal chemistry is discussed. 
"#

ADMET, MMPA, matched molecular pair analysis, data sharing, data mining, big data, 
unsupervised learning, precompetitive research, medicinal chemistry knowledge.
$

Medicinal chemistry is a discipline at the borderline of science and technology that 
depends on experience, intuition and knowledge of rules that govern the space of medicinal 
chemistry practice. As such, successful medicinal chemistry optimization has routinely drawn 
on knowledge gained from past experimental observations. Thus it is fair to assume that the 
more data are available (everything else remaining equal), the more knowledge can be 
gained. 
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While more data is desirable, the strategic necessities in a patentCbased competitive 
environment allow the public sharing of only a small proportion all of the information 
generated inside pharmaceutical companies. In particular, the composition of chemical matter 
with its associated biological properties is a cornerstone of pharmaceutical patent filing. 
Therefore parties interested in protecting their research must exercise great care in the 
chemical structures they disclose either in a patent or in academic publications not to weaken 
any patent position.  It is therefore unsurprising that only a small proportion of chemical 
structures synthesized and their assay data tested are ever made public. As medicinal 
chemistry knowledge is the understanding of the relationships between chemical structure 
and biological properties, this creates a conflict between gaining knowledge and maintaining 
intellectual property.   
In order to increase our knowledge space, we set out on an experiment to combine 
absorption, distribution, metabolism, and toxicity (ADMET) data from three different large 
pharmaceutical companies (AstraZeneca, Genentech, and Roche; Genentech research and 
Roche research operate independently) and mine the pooled data for relevant medicinal 
chemistry knowledge. MedChemica was used as the intermediary to combine rules. In 
particular, we were interested in whether we could merge ADMET knowledge between the 
companies, and whether we could synergistically increase our medicinal chemistry 
knowledge based upon the joint information pool. 
A solution to sharing large amounts of medicinal chemistry data between companies in 
the patentCbased competitive environment is to use matched molecular pair analysis 
(MMPA),
1–7
 since the original structures of the compounds cannot be calculated back if only 
the part of the structure which is involved in the transformation is shared.
8
 MMPA extracts 
transformations that link a pair of compounds. For all pairs that are linked by the same 
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transformation, MMPA calculates aggregate statistics of the property differences to derive a 
rule for the given transformation. In this work we use the term “rule” to indicate a “virtual” 
chemical transformation leading to a change in a physical chemistry or biological endpoint 
where there are enough examples to support an assertion as to how this change influences 
certain given molecular properties. Very rarely, there are transformations where all known 
pairs change property in the same direction, in particular if there are many pairs. 
Nevertheless, even in the presence of exceptions, knowing the most common effects is useful 
to guide whether or not a compound shall be made. The rules therefore capture variability, 
which is a crucial element in medicinal chemistry decision making. Obviously more than one 
pair is needed for a rule to be more than an anecdote; the statistical approach used here 
suggests an absolute minimum of six pairs should be considered in order to form a rule. One 
of the most important attributes of MMPA is its closeness to medicinal chemistry reasoning, 
where talk of “adding a fluorine to block metabolism” or “adding a solubilizing group” are 
common descriptions of underlying thinking. Occam’s razor suggests that the simplest cause 
for a change in a property is the single change in structure. Neighboring groups within the 
molecules involved may also play a causal role, hence, the local chemical environment is 
incorporated into the encoding of the structural change and should allow these effects to be 
partitioned and examined separately.
9
 The only remaining explanations are long range effects 
or nonCadditivity of chemical changes. Kramer et al showed that SAR nonCadditivity may be 
masked due to experimental uncertainty in many cases, and in other cases depends on the 
target and binding mode.
10
 
There have been significant studies, already published, describing the application of 
MMPA to ADMET datasets from individual pharmaceutical companies.
2,11,12
 Most of these 
have been supervised analyses, where a particular question is asked such as “what effect does 
hydrogen replacement on an aryl ring have on ADMET properties”
13,14
 or “what are the 
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effects of substituting different heterocycles for phenyls”.
12
 In contrast, here we attempt to 
characterize the entire ADMET rule space. 
Having developed the technology to merge data between companies (details can be found 
in supporting information), the next question becomes: “How many extra rules do we gain 
and is there any degradation in knowledge by merging data between companies?” It is 
relatively obvious that by aggregating pairs from different companies the statistics for some 
rarer transformations will become significant because there are more pairs. However, this 
gain may be obfuscated by noise introduced due to mixing data from assays with the same 
endpoint but run under different conditions.
15
 A major concern is assay comparability: 
although two companies may formally measure the same ADMET attribute, if the assays 
used are different the outcomes may be different. The advantage of MMPA here is that two 
compounds are only compared if they have been measured by the same operator using the 
same method and endpoint. The difference in an attribute between two compounds is then 
calculated. If the assays are merely systematically displaced against other, then the systematic 
displacement is automatically factored out by using differences rather than absolute values. It 
is then possible to test if pairs can be aggregated across different assays and rules identified. 
To validate this, we (a) compare the rules we found by aggregating pair sets across 
companies to rules obtained from one company only and (b) to rules previously published. 
HighCquality analysis from MMPA requires large amounts of data, and we will show that 
more data is clearly better with brief examples of analyses that can be made using such a 
massive dataset. We will illustrate the types of analyses that can be done having a rule pool as 
large as ours. We initially present general analyses of correlations of solubility, clearance, 
and PPB rules with logD (pH 7.4) rules. As rules representing general knowledge are always 
accompanied by exceptions, we highlight a few lessCintuitive medicinal chemistry rules that 
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counter the general trends. Finally, we give a taste of how such a huge set of rules can be 
used to characterize individual functional groups, a statistical type of analysis which only 
becomes possible once large MMP datasets are available. It is not our intent to hypothesize 
the cause of a particular quoted rule being significant as a thorough exploration of the rules 
has been beyond the scope of this work, and value can be obtained from their knowledge 
without complete clarity as to their causation. 
	


Data needs to be transformed into a normally distributed variable before MMPA 	
pIC50, log10 (molar solubility), log10(intrinsic Clearance, (CLint)) for in vitro clearance assays, 
log(free/bound) for protein binding etc. Out of range flags were attached where appropriate. 
If there were multiple measurements in the same assay for the same compound then the data 
were aggregated using the following scheme: 
1.     Where there are no qualifiers / out of range flags: 
·    aggregate as median logged value – as this is more representative of true value 
than mean, and less sensitive to outliers 
2.     Where there are some qualified data present: 
·     take the median of the data excluding qualified data: 
  For example: 3, 6, >8, >10, <3, 5, 6: exclude >8, >10, <3, the 
median(3,6,5,6)=5.5 
3. If there are only qualified data present: 
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·       if there is a mixture of > and < then discard the data 
·       if the qualifiers are all < then use the minimum value 
·       if the qualifiers are all > then use the maximum value. 
We used logD7.4, solubility, in vitro microsomal and hepatocyte clearance (human, rat, 
mouse, cynomolgus monkey, dog), Madin Darby Canine Kidney cells (MDCK cells) 
permeability (ACB,  B–A and efflux), cytochrome P450 inhibition (2C9, 2D6 , 3A4 , 2C19 , 
1A2), NaV 1.5 and human etherCaCgoCgo related gene product (hERG) ion channel inhibition, 
glutathione stability, and PPB (human, rat ,mouse, cynomolgus monkey, dog) assays. We 
have not addressed explicitly the propagation of experimental errors, or the heteroscedasticity 
of assay data.
16
 In keeping with a “Big Data” paradigm we have chosen to include as much 
measured data as possible and to use nonCparametric statistics to generate inferences that may 
be more resistant to the effects of noise. 
	
	!		!
Compound structures were extracted as SMILES, desalted and had their charge corrected 
to the neutral form by applying SMIRKS using the Openeye OEChem toolkit. A set of 
SMIRKS were applied to recursively standardize tautomers to a common form. These were 
not intended to be completely accurate tautomeric forms for a given physical state, but to 
provide a unique canonical standard. For chiral compounds, racemates were excluded from 
the analysis. No further filters were applied to the inclusion of compounds. 
An MMP analysis platform, MCPairs, was used that combines the benefits of the Hussain 
and Rea algorithm
17
 with those of the WizePairZ algorithm.
18
 Compounds were fragmented 
on all noncyclic single bonds except amide (CCN) and sulfonamide (SCN) bonds. 
Fragmentations of up to three cuts were created. Pairs were matched based on a joint constant 
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part, and the nonCidentical parts were taken as the transformations. The transformations were 
recorded as SMIRKS with explicit hydrogens to ensure correct aromaticity and 
tautomerization assignment. For a matched pair change, the local chemical structures up to 
four bonds from the point of change were captured, which we classify as the “environment” 
in the same manner as in WizePairZ. Note that within this formalism, two compounds can be 
linked by several transformations. Pairs were only considered if the part encoded in the 
SMIRKS did not make up more than 45% of the molecule and the number of nonChydrogen 
atoms in the changing part of the transformation was 16 or fewer. Pairs were not used if the 
measured activities for both compounds have a qualifier of the same direction, for example 
both compounds were measured as > X. An example for a pair is given in Figure 1. More 
examples can be found in the supporting information Figure S1. 
 
 
 
Molecule Pair                                                   
 
Molecule A         →          Molecule B 
 
 
3 bond environment 
   
     
[c:1]([H])[c:2]([H])[c:3]([H])[c:4]([H])[n:5]>> 
[c:1]([H])[c:2]([H])[c:3]([c:4]([H])[n:5])[C]([H])([H])([H]) 
 
Page 8 of 54
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Figure 1: Functional group transformation with environment specification of 3 bonds as 
chemical sketch and as SMIRKS notation (examples for other environments can be found in 
the supporting information). The green groups are those being changed in the transformation, 
the red portions of the transformations show the increasing level of environment specification 
increasing in all directions from the point of change. The blue atom numbers correspond to 
the atom mappings in the SMIRKS transformation encoding. 
%#
Data extraction, manipulation and analysis were performed using scripts written in 
Python
19
 using the Openeye cheminformatics toolkit
20
 for chemical structure manipulation. 
MySQL
21
 was used for database infrastructure and statistical routines were implemented in 
R
22
 using the rpy2
23
 interface to Python. 
&'
MMP identification was carried out within each contributing company behind their 
firewalls.  Data tables of the transformations with the particular biological or physical 
chemistry delta values and associated calculated properties were then supplied to 
MedChemica as a neutral third party. These data tables excluded the original compound 
structures. The overall concept is shown in Figure 2. 
 Complete isolation of different companies’ data was ensured by MedChemica acting as a 
neutral third party and conducting all knowledge extraction through aggregation and filtering. 
This ensured that there could be no “drill down” from any rule to any companies’ 
substructures or data by multiple layers of anonymisation. 
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 Figure 2: General assembly and use concept for the Grand Rule Database 
To cover different possibilities, rule statistics were calculated in two different ways. 
Assuming that the differences between all pairs are normally distributed, median, standard 
deviation, and standard error of the mean was calculated for each transformation. Since many 
transformation involve censored data (	 measured values with “>” or “<” signs), nonC
parametric statistics based on a twoCtailed binomial test were calculated to detect whether a 
given transformation significantly increases or decreases a property. Since the twoCtailed 
binomial test requires at least six pairs for significance at the p=0.05 level, all rules with less 
than six pairs were discarded. An additional feature of this approach is that chemical 
transformations that have only been tried very few times will not be shared amongst 
contributing parties. There is a tension in this choice in that these may be  “emerging” novel 
medicinal chemistry approaches which would be valuable to further explore, but in contrast 
Page 10 of 54
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
these may be the “novel” medicinal chemistry approaches being most recently developed 
within a company and for which they wish to maintain an advantage. More details on the rule 
processing can be found in the supporting information. 
When only one company contributed to an ADMET endpoint, the rules extracted by this 
process were added to the grand rule database (GRD). Where biological or physical 
chemistry endpoints could be compared between companies, the statistically significant 
transformations (according to the twoCtailed binomial test) were extracted for calibration 
from each company set, and then the intersection set of transformations (those with identical 
canonical SMIRKS) was found.  This intersection set was used to define calibration factors 
between the assays using a twoCway Analysis of Variance (ANOVA) procedure.
24
 A 
minimum of 8 transformations in the intersection set was required for calibration. Each of the 
transformations required a minimum of 6 matched pairs. If there were more than 200 
transformations in the intersection set, a random subset of 200 transformations was used. As 
all transformations are mirrored, (AB and BA directions) for any given pair of 
transformations, only the positive median direction transformation was used to avoid a 
significant overestimation of the correlation between contributors as obviously delta AB  =   
C1* delta BA. The mean change for the set of transformations, the means by contributor 
and the grand mean coefficients were taken from the ANOVA coefficients. The calibration 
factors for each contributor were calculated as the ratio of the grand mean over contributor 
mean. Each contributors data set was then scaled by the calibration factor and reCaggregated 
to generate a ‘common calibrated value’ representing the best estimates for each 
transformation.  Merging all pairs with adjusted differences into rules gave a significant 
synergy benefit, where for example a transformation that had only 3 examples from one 
company, 2 from another and 1 from a third company could now pass the binomial test if all 
Page 11 of 54
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
the examples changed the property in the same direction. The scaling procedure is 
schematically shown in figure 3. 
 
 
Figure 3: Linearly displaced assays of different sensitivity 
 The statistical methods appropriate for this comparison have been developed in the 
clinical chemistry arena to allow different laboratories to compare their results against each 
other
25
 and more generally in the metaCanalysis of clinical trials.
26
 This is equivalent to the 
established medicinal chemistry practice of recording the ranking of changes in extracting 
knowledge from publications or presentations; the exact values might be different but the 
ranking should be the same. It is reasonable to assume that scientists constructing assays in 
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different organizations will have developed them such that they give the same ranking of 
standard compounds if not an identical numeric result. 
&
&
Over all the sets of assay data analyzed, 43 million unique structural transformations were 
found.  372,419 of these had more than six examples in any assay and passed the binomial 
test, each forming a medicinal chemistry rule. The distribution and overlap in rules per 
company is shown in figure 4. 
 
Figure 4: The origin of rules by company. The overlaps indicate the rules that contain 
examples from multiple companies, 	 58,000 rules had examples from all three companies, 
139,000 rules were derived from company A data only.  
A key question is: “what does a company gain from sharing data with the others”. In 
numeric terms the average gain in rules for a company is 350% C 	 if a company found 100 
rules from analyzing its own data sets, it would have 450 rules by joining the consortium. On 
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average this indicates how much nonCoverlap there has been between medicinal chemistry 
practice, with a large number of rules resulting from swapping knowledge from different 
areas.  Also we can calculate the synergistic gain as the increase in number of rules found by 
merging the pairs and analyze the combined set minus the sum of what companies would 
have found individually, the average synergistic gain was 17%.  This is the proportion of 
rules that had too little statistical support in any individual company, but “appear” by 
merging data. Some insight into the question “how large is the medicinal chemistry tool kit“ 
can also be addressed using this dataset, since the number of unique transformations can be 
extracted. For the 372,419 transformations that have been tried enough times to be assessed, 
there were  126,064 different A→B modifications when ignoring the local chemical 
environment. This also suggests that medicinal chemists in different companies are working 
in different areas of chemical space.
27–29
 Analysis of the frequency of matched pairs showed a 
Zipfian distribution as previously reported by Hussain and Rea.
17
 An example is shown for 
one company in the consortium’s contribution of human microsomal clearance data, of the 
400,191 observed matched pairs, there were 303,966 unique SMIRKS. A breakdown of the 
numbers of examples of SMIRKS is shown in Figure 5. 86% of the transformations were 
only observed once, with only 1% being observed six or more times. 
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 Figure 5: Distribution of number of pairs per transformation for a single company’s 
human microsomal clearance data 
%
The distribution of calibration factors from all assay comparisons across all properties is 
shown in Figure 6. The calibration factors showed a median of 1.02; 80% of the calibration 
factors lie between 0.78 and 1.15 with two of the  low outliers being assays where different 
technologies were used for signal detection. This suggests that, with appropriate care, the 
combination of data from multiple sources is feasible and that for most properties, different 
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companies operating the same methods for a property determination generate comparable 
changes in measured values. 
 
Figure 6: Distribution of the calibration statistics (median shown in black), count 
indicating the number of assays for a given bin. 
&(

One of the key questions for merging data between companies is how well these data 
agree with one another, or in other words, if and how much noise is added by merging the 
data. In our approach, we only formed pairs between compounds that have been measured in 
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the same assay. It has been demonstrated that forming pairs between compounds that have 
been measured in assays that formally measure the same endpoint but are run by different 
operators in different places could increase the uncertainty of the rules dramatically, and the 
number of additional pairs gained is unlikely to compensate for the noise introduced.
15
 For 
GRD, we compared the rules gained from a single company database (Roche as an example) 
versus the GRD rules (see figure 7) to compare the rules before and after the merging. 
 
Figure 7: Correlation between predicted changes in logD based on Roche only rules and 
joint companies’ rules. Overall R
2
 is 0.98. Unless stated otherwise, in this and all succeeding 
scatterplots the pale green density ellipse contains 99%. The red line is the line of slope 1, 
intercept 0. The blue line indicates the linear fit. In this case the vast majority of the data lies 
on the 1:1 line between median logD change of C2 and +2 making the density ellipses hard to 
see. 
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For logD, the rules derived from Roche only data and the rules derived from the joint set 
of pairs compare extremely well with an R
2
 of 0.98 and an RMSE 0.09. Overall, there are 
255k logD rules in the GRD and 81,617 rules based on Roche data alone. 
LogD is a relatively simple property to measure, depending on the equilibrium of a 
compound between two different solvents. Other important properties are more complicated, 
and their reproducibility and transferability between companies is likely lower. In Figure 8 
we show the correlation between rules for human microsomal clearance derived from Roche 
data alone and the joint companies’ data. 
 
Figure 8: Comparison between RocheConly and GRD rules for human microsomal 
clearance. Overall R
2
 is 0.76 and RMSE 0.11. 
 
Overall, with R
2
 = 0.76, the correlation for the microsomal clearance rules is lower than 
for logD. Nevertheless, almost all rules agree qualitatively, and only in 64 out of 933  the 
prediction changes from a negative to a positive median difference or vice versa (see 
Supporting Information on how positive, negative, and neutral effects are statistically defined 
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in this work). Some of the rules in GRD shown in Figure 8 are based almost exclusively on 
Roche data. Those obviously lie close to the line of unity. For other rules, there are very few 
pairs from Roche only, and for a subset of those rules, the Roche contributing pairs had 
almost no change in clearance. The rules in that subset are visible as a horizontal line. Being 
more restrictive about the inclusion criteria for the comparison, those apparent lines 
disappear, but the overall correlation is the same (data not shown). 
)&((
Since the overall comparison is very favorable, we were interested in finding out how 
individual rules from GRD compare to previously published rules. In 2015, Huchet 	
  
published a paper on fluorine effects and their impact on physicochemical properties.
30
 From 
prototypical examples given for logD, we extracted MMPs and compare them with the 
statistics for the closest transformation we could find in GRD (see table 1). 
Fluorine can have a large effect on the pKa of a nitrogen in close vicinity. Therefore, 
transformations were selected with a balance between the number of pairs, chemical 
similarity, and being sure that no ionizable center is affected. We did not find contextually 
very close analogs of the compounds presented by Huchet 	
 . In the congeneric 
transformation series we found, an aromatic ethoxy group is increasingly fluorinated, 
whereas in the Huchet 	
  paper an aromatic propyl group is increasingly fluorinated. 
Nevertheless, the trend reported by Huchet 	
 is the same as the trend we find in GRD: a 
single fluorination reduces logD most strongly, whereas further fluorinations will reduce this 
effect. 
Source Transformation [logD ± 
std (nPairs) 
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Huchet 
 
 
C0.7 
GRD 
 
[c:1]([H])[c:2]([c:3])[O:4]C([H])([H])C([H])([H])([H])>>[c:1]([H])[c:2]([c:3])[O:4]C([H])([H])C([H])([H])F 
C0.48 ± 
0.72 (8) 
Huchet 
 
 
C0.6 
GRD 
 
[c:1][O:2][C]([H])([H])[C]([H])([H])([H])>>[c:1][O:2][C]([H])([H])[C]([H])([F])[F] 
C0.11 ± 
0.28 (18) 
Huchet 
 
 
C0.4 
GRD 
 
[c:1][O:2][C]([H])([H])[C]([H])([H])([H])>>[c:1][O:2][C]([H])([H])[C]([F])([F])[F] 
0.21 ± 0.59 
(50) 
Huchet 
 
C0.8 C C1.0 
GRD insufficient examples Insufficient 
examples 
Table 1: Comparison between Fluorine effects published by Huchet 	
 and GRD statistics. 
Here and in all following transformation depictions, the green bar indicates the bonds that 
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separate the constant and the variable part of the transformation. The atoms that are depicted 
and belong to the constant part are the atoms defining the environment of the transformation. 
As a second comparison, we looked at amide/ sulfonamide methylation. In one of the first 
MMP analysis papers, Leach 	
 statistically showed that amide NCmethylation increases 
solubility.
2
  Subsequently Ritchie 	
 presented statistics showing that on average, amide 
methylation on aromatic amides reduces logD and increases solubility.
31
 They rationalize this 
behavior with the planarityCbreaking effect of aromatic amide NCmethylation. In contrast to 
amide NCmethylation, they show that sulfonamide methylation always increases logD and 
reduces solubility. The GRD data is in perfect qualitative agreement with their observation 
(see table 2): In our data, aromatic amide NCmethylation on average decreases logD by 0.25 
log units and improves solubility by 0.26 log units. In contrast, aromatic sulfonamide NC
methylation increases logD by 0.37 units and decreases solubility by 0.10 log units. Note that 
the rules used here are not merely hydrogen to methyl transformations, but rather specific 
linker transformations as depicted in table 2. 
Transformation [logD ± std 
(nPairs) 
 
[Solubility ± std 
(nPairs) 
 
[c:1][C](=[O])[N]([H])[C:2]([H])([H])([H])>>[c:1][C](=[O])[N]([C:2]([H])([
H])([H]))[C]([H])([H])([H]) 
C0.25 ± 0.45 (190) 
 
0.26 ± 0.87 (144) 
 
[c:1][C](=[O])[N]([H])[C:2]([H])([H])([H])>>[c:1][S](=[O])(=[O])[N]([H])[C
C0.19 ± 0.41 (64) 
 
C0.10 ± 0.48 (23) 
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:2]([H])([H]) 
 
[c:1][C](=[O])[N]([C]([H])([H])([H]))[C:2]([H])([H])>>[c:1][S](=[O])(=[O])[
N]([C]([H])([H])([H]))[C:2]([H])([H]) 
0.79 ± 0.21 (6) 
 
insufficient 
examples 
 
[c:1][S](=[O])(=[O])[N]([H])[C:2]([H])([H])>>[c:1][S](=[O])(=[O])[N]([C]([
H])([H])([H]))[C:2]([H])([H]) 
0.37 ± 0.35 (18) 
 
C0.10 ± 0.67 (17) 
Table 2: Effect of changing a secondary into a tertiary aromatic amide/ sulfonamide on 
solubility. 
Another comparison with rules previously identified by Papadatos 	
 
9
 is detailed in 
the supporting information Table S17. We generally find that the rule statistics found in GRD 
compare very well to previously published rule statistics. Differences result from different 
encoding of the environment, sampling (both number of pairs and chemical diversity), and 
interCcompany variations in measuring different endpoints (see paragraph on Roche vs. joint 
rules). 
%(
The most basic physicochemical parameters of relevance for drug design are solubility 
and logD. Initially we explored separating the thermodynamic and kinetic solubility assays. 
However we discovered that the assays, although known to give different absolute values, 
give the same compound rankings therefore rules could be inferred from combining the 
mixed solubility data sets.  This is a quantitative equivalent to medicinal chemistry practice 
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of inferring what are good “solubilizing groups” irrespective of solubility assay. LogD and 
solubility are often highly correlated, with the only other dominant factor apart from 
lipophilicity that influences solubility being the stability of the crystal structure, which can be 
measured by the melting point. 
32
 A plot of the correlation between the solubility and logD 
rules is shown in figure 9. 
 
Figure 9: Solubility vs logD effects, >=20 pairs per rule, n=13453. R
2
 = 0.66, slope = C0.57, 
intercept = 0. Red line: line of slope C1, intercept 0. Unless stated otherwise, in this and all the 
succeeding scatterplots, the dark green ellipse contains 50% of the data. 
Figure 9 shows that logD and solubility are also highly correlated in transformation space. 
The R
2
 is 0.66, with a slope of C0.57. If only rules with at least 50 pairs are considered, the R
2
 
increases to 0.72 (graph not shown).  This means that on average a change of 1 in logD 
translates into a solubility change less than one order of magnitude. However the breadth of 
the distribution should be noted. For isolipophilic transformations, 	 those with a [logD of 
0, the change in solubility can range over +/C 1 log unit. 
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There are a number of rules that have good statistical support but break the 
logD/solubility correlation, three examples are shown in table 3. 
Transformation [logD ±std
 (nPairs) 
[logSol ±std 
(nPairs) 
 
[C:1]([H])([H])[C:2]([H])([H])[N]1[C]([H])([H])[C]([H])([H])[O][C]([H])([H
])[C]([H])([H])1>> 
[C:1]([H])([H])[C:2]([H])([H])[N]1[C]([H])([H])[C]([H])([H])[C]([H])([H])[
C]([H])([H])[C]([H])([H])1 
0.00 ± 0.67 (91) 0.73 ± 0.72 (87) 
 
[C]([H])([H])([H])[C]([C]([H])([H])([H]))([C:1]([H])([H]))[O:2]([H])>> 
[C:1]([H])([H])[C]([H])([H])[O:2]([H]) 
C0.59 ± 0.49 
(82) 
0.03 ± 0.72 (98) 
 
[c:1]1([H])[c:2]([c:3]([H])[c:4]([c:5][c:6]1[Cl:7])[Cl:8])[C]#[N]>>[c:2]1([H])
[c:1]([H])[c:6]([c:5][c:4]([c:3]1([H]))[Cl:8])[Cl:7] 
0.45 ± 0.64 (50) 0.46 ± 1.02 (65) 
Table 3: Example transformations where the change in logD and Solubility is not as one 
would expect from the logDCSolubility correlation. 
The medians for the examples shown in Table 3 are statistically all very well backed, 
although there is quite some variation for the individual pairs as can be seen from the 
standard deviations. In the first example, an aliphatically NCconnected morpholine is 
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exchanged by an aliphatically NCconnected piperidine.. In the second example, a tertiary 
dimethyl alcohol is transformed into a primary alcohol. This on average reduces logD by 0.59 
log units, but has almost no effect on solubility. In the last example, a 4CcyanoC2,5C
dichlorophenyl is transformed into a 2,5Cdichlorophenyl. This transformation increases logD 
by 0.45 log units, but it also increases solubility by 0.46 log units. From this and other 
examples (see supporting information) we have seen, it appears that aromatic cyano groups 
do not help for solubility. In the supporting information, some additional transformations 
with unexpected relationships between the effect on logD and solubility are exemplified in 
Table S5CS7. 
(
Reducing lipophilicity is often considered as a common strategy to improve metabolic 
stability. In fact, 19 of GRD’s top 20 rules (see Table S8 in supporting information) that 
decrease liver microsomal clearance and hepatocyte clearance are also accompanied by a 
logD decrease. Figure 10 shows a plot of the median change of microsomal and hepatocyte 
clearance in human and rat against the corresponding median change in logD where we have 
> 20 examples. (Microsomal and hepatocyte clearance data was used as pure Clint values, 
uncorrected for binding.) The plot shows a good correlation between these two properties 
(R
2
=0.40 and 0.30 in human and rat microsomal clearance vs logD and 0.34 and 0.41 in 
human and rat hepatocyte clearance vs logD). The plot suggests that on average a change of 1 
in logD translates into a human or rat inCvitro clearance change of 0.2 C0.4 log units. 
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(a) 
(b) 
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(c) 
(d) 
Figure 10: Median change of logD vs median change of (a) human (n=11,572, R
2
=0.40, slope 
= 0.23) and (b) rat (n=5,056, R
2
=0.30, slope = 0.20) liver microsomal clearance. Median 
change of logD vs median change of (c) human (n=812, R
2
=0.33, slope = 0.31) and (d) rat (n 
= 4,937, R
2
=0.41, slope = 0.24) hepatocyte clearance. Data is only shown for rules based on 
>=20 example pairs for every transformation. 
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There are some transformations that reduce human microsomal clearance while keeping 
logD neutral or even increasing it. Table 4 shows three such examples. 
Transformation 
Human 
microsomal 
Clearance median 
change ± std 
(nPairs) 
logD
median change ± 
std
(nPairs) 
 
[c:1][c]1[c]([H])[n]([H])[n][c]([H])1>> 
[c:1][c]1[c]([H])[n][n]([c]([H])1)[C]([H])([H])[C]([H])([H])([H]) 
C0.34±0.71 
(13)  
0.35±0.45 (15)  
 
[c:1][c]1[c]([H])[c]([H])[c]([H])[c]([H])[c]([H])1>> 
[c:1][c]1[c]([H])[c]([H])[c]([c]([H])[c]([H])1)[Cl] 
C0.32±0.51 
(53)  
0.7±0.74 (117)  
 
[c:1][S](=[O])(=[O])[C]([H])([H])[C]([H])([H])[O][C]([H])([H])([H
])>> 
[c:1][S](=[O])(=[O])[C]([H])([H])([H]) 
C0.59±0.38 
(14)  
0.0±0.11 (19)  
Table 4: Transformations that decrease human microsomal clearance while keeping logD 
constant or even increasing it. 
In the first transformation shown, a potentially reactive pyrazoleCNH is protected by an 
ethyl. This increases logD by 0.34 log units, but at the same time on average reduces 
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clearance by 0.34 log units.
33
 In the second example, a terminal unsubstituted phenyl ring is 
substituted with chlorine in the para position. This leads to a drastic increase in logD by 0.7 
log units, but also to an average decrease in clearance by 0.32 log units. Fluorine in the para 
position of a phenyl ring did not produce same statistical effect as chlorine; details of chlorine 
and fluorine substitution on a phenyl ring are in Table S9 in the supporting information.  In 
the last transformation, an aromatic methoxyCethylCsulfone is replaced by a methyl sulfone. 
This on average does not have any effect on logD, but it strongly reduces clearance by 0.59 
log units. In the supporting information (Table S10C12), more examples of transformations 
that reduce clearance while keeping logD constant or even increasing it are provided. 
!!*(
The optimization of free fraction as a goal is open to debate,
34
 however when chosen as a 
strategy, reducing logD to increase the free fraction is an accepted approach.
35
 We expect to 
observe the general trend between logD and free fraction in our data. In the GRD, changes in 
logD and human free fraction correlate fairly well for rules with more than 20 examples. 
Many outliers belong to the group of transformations where there is a change in anion count 
(colored blue in figure 11). Those are mainly neutral to acidic or acidic to neutral 
transformation changes, which have previously been reported to be “special” for free 
fraction.
36
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 (a) 
 
(b) 
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 (c) 
Figure 11:  human free fraction vs logD effect: red line = slope C1, intercept 0. (a) Greater 
than or equal to 20 pairs per rule and neutral: R
2
= 0.71, Slope= C0.45, 7942 rules. (b) Rules 
with anion increase not equal to zero: R
2
= 0.06, Slope= C0.03, 192 rules. (c) Rules with cation 
increase not equal to zero: R
2
= 0.90, Slope= C0.58, 738 rules. 
Figure 11 shows that differences in free fraction are highly correlated with differences in 
logD (R
2
= 0.73, Slope= C0.46, 8,680 rules, not visible from these plots), if no anions (	 
acids) are introduced or removed. This is a valuable finding, since it means that [logD can be 
used as a good surrogate for human [log(free/bound), if no exchange of anions is involved. 
Despite have a huge effect on logD, the addition or removal of anions on average has no 
effect on PPB, as can be seen from figure 11b. The change in logD due to introduction or 
removal of cations, in contrast, is again highly correlated to the change in PPB, as can be seen 
from figure 11c. If the free fraction is low, it becomes very hard to measure, and 
improvements in free fraction can in many cases not be monitored experimentally since they 
are still below the limit of detection. 
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Some free fraction transformations are counterintuitive because logD is either increased 
or constant, but the free fraction increases nevertheless, and an acid is not involved in the 
transformation. Table 5 shows three such examples. 
 
Transformation [logD ±std
(nPairs) 
Hu[log 
(free/bound ±std
(nPairs) 
 
[c:1][n:2]([c:3])[C]1([C]([H])([H])[C]([H])([H])[O][C]([H])([H])[C]([H])([H])1)[
C]([H])([H])([H])>> 
[H][C@@]1([C]([H])([H])[C]([H])([H])[C@]([C]([H])([H])1)([H])[O][C]([H])([H
])([H]))[n:2]([c:1])[c:3] 
0.33 ± 0.14 (11) 0.32 ± 0.34 (11) 
 
[c:1][O][c]1[c]([H])[c]([H])[c]([c]([H])[c]([H])1)[C:2]([H])>> 
[c:1][C]([H])([H])[c]1[c]([H])[c]([H])[c]([c]([H])[c]([H])1)[C:2]([H]) 
0.48 ± 0.29 (11) 0.42 ± 0.28 (12) 
 
[c:1][N:2]([C:3]([H])([H])([H]))[c]1[c]([H])[c]([H])[c]([c]([c]([H])1)[C]([H])([H])
[O]([H]))[C]([H])([H])([H])>>[c:1][N:2]([C:3]([H])([H])([H]))[c]1[c]([H])[c]([c]([
H])[c]([H])[c]1[C]([H])([H])([H]))[C]([H])([H])[O]([H]) 
C0.1 ± 0.11 (21) 0.62 ± 0.19 (7) 
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Table 5: Transformations that increase the free fraction and increase or keep logD almost 
constant. 
The first transformation in table 5 shows the conversion of a 4Cmethyl tetrahydropyran 
into a methoxyCsubstituted cyclopentyl. This on average increases the free fraction by 0.32 
log units, but also increases logD by 0.33 log units. The second transformation shows the 
conversion of an OClinker between two aromatic rings into a CH2Clinker. LogD is increased 
by 0.48 log units, while the free fraction is increased by 0.42 log units. The last 
transformation in table 5 shows the shift of a methyl group on a substituted phenyl from the 
para to the ortho position.  LogD is not significantly changed, but the free fraction is 
increased by 0.62 log units. More examples can be found in the supporting information Table 
S14CS16. 
+

Having a huge and diverse MMP database (over 350k unique structural transformations 
each with more than 6 example pairs) such as the GRD allows for a characterization of 
functional group replacements across many ADMET attributes. For frequently applied 
transformations such as the ones shown in Tables 6 and 7, almost complete “functional group 
scorecards” can be derived to predict the effect of a given frequent transformation on 
ADMET and PhysChem properties, normalized to a common starting structure. The 
scorecards give a quick overview of functional group properties across many different 
attributes relevant to drug design. Differences in the behavior of the pyridine and chloroC
phenyl isomers is, as we might anticipate, smaller for the ADMET attributes where the 
interaction is less specific such as solubility, logD and protein binding, and larger for the 
more specific interactions such as P450 and hERG inhibition. Although we could speculate 
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on the reasons for the regioisomer differences, detailed exploration of the causes of these 
differences is beyond the scope of this work. 
!

   
 
Property [ ± std (nPairs) [ ± std (nPairs) [ ± std (nPairs) 
logD* C0.64 ± 0.70 (75) C0.92 ± 0.72 (70) C0.87 ± 0.79 (54) 
Solubility 1.00 ± 0.75 (98) 0.84 ± 0.80 (98) 0.79 ± 0.81 (77) 
hERG C0.39 ± 0.47 (57) C0.36 ± 0.44 (24) 0.12 ± 0.54 (37) 
PPB human* 0.31 ± 0.42 (32) 0.73 ± 0.42 (37) 0.79 ± 0.38 (17) 
human Mic 
Clearance 
C0.11 ± 0.46 (43)* C0.07 ± 0.57 (90) Insufficient 
examples 
human Hep  
Clearance 
C0.28 ± 0.30 (8) C0.14 ± 0.13 (5) C0.04 ± 0.30 (7) 
CYP3A4 
inhibition 
C0.31 ± 0.49 (22) 0.65 ± 0.54 (20) 0.96 ±0.67 (21) 
CYP2D6 
inhibition 
C0.41 ± 0.51 (8) 0.49 ± 0.52 (7) 1.08 ± 0.66 (8) 
CYP2C19 C0.69 ± 0.74 (3) 0.01 ± 1.11 (8) 0.74 ± 0.91 (6) 
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inhibition 
Table 6: Effects of changing a phenyl into a orthoC, metaC, and para Cpyridine.* [R1][C] 
instead of [R1][C]([H])([H]) taken as environment due to paucity of pairs. 
, ' ' !
  
 
 
 
Property [ ± std (nPairs) [ ± std (nPairs) [ ± std (nPairs) 
logD 0.48 ± 0.60 (66) 0.58 ± 0.57 (86) 0.67 ± 0.75 (127) 
Solubility C0.36 ± 0.77 (42) C0.38 ± 0.75 (50) C0.52 ± 0.85 (81) 
hERG C0.04 ± 0.29 (14) 0.16 ± 0.27 (5) 0.38 ± 0.35 (25) 
PPB human C0.33 ± 0.34 (32) C0.49 ± 0.39 (51) C0.54 ± 0.39 (68) 
human Mic Clearance 0.24 ± 0.53 (47) 0.20 ± 0.47 (49) 0.00 ± 0.38 (61) 
human Hep  
Clearance 
0.16 ± 0.38 (7) 0.30 ± 0.29 (16) C0.01 ± 0.37 (20) 
CYP3A4 inhibition 0.29 ± 0.49 (20) 0.27 ± 0.46 (22) 0.27 ± 0.55 (31) 
CYP2D6 inhibition 0.09 ± 0.36 (9) 0.20 ± 0.37 (12) 0.16 ± 0.54 (24) 
CYP2C19 inhibition 0.32 ± 0.70 (5) 0.37 ± 0.61 (8) 0.16 ± 0.68 (14) 
Table 7: Effects of orthoC, metaC, and para Cchloro substitution on benzyls. 
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
We have determined whether medicinal chemistry ADMET knowledge can be shared and 
enhanced by combining transformations between organizations. Using the MMPA 
technology, knowledge about the effects on ADMET properties of medicinal chemistry 
transformations can be generated based on the joint pair datasets from all participating 
companies. The number of rules gained increases synergistically, since there are cases where 
the significance threshold to define a rule is only reached by adding all pairs linked by the 
same transformation from different companies.  
Examining the effect of the transformations on human liver microsomal stability and 
LogD common to all contributing organizations to those from Roche alone shows excellent 
agreement. This shows that the merging data by the strategy presented in this contribution 
supplements inhouse rules much more than it increases the noise in the rule statistics due to 
mixing pairs measured at different companies. Although an exact quantitative comparison 
with previously published rules is not possible due to different MMPA definitions used in 
different publications, we observe qualitative agreement between the GRD rules and 
published rules.  At first sight the synergistic gain may appear purely quantitative (more 
rules), it is important to realize, however, that the more pairs support those rules, the better 
they become. Therefore, ‘quantity has a quality all its own’ in MMPA. Also, if the pairs come 
from different companies, the structural variety in the underlying pairs most probably 
increases, making the rules more robust. We did not quantify this here, but we believe that in 
future work it would be valuable to develop a metric for quantifying the structural diversity in 
the underlying pairs for each rule as an indicator of robustness. 
The correlation between logD and solubility in transformation space, 	 the space that is 
relevant for medicinal chemistry optimization, has an R
2
 of 0.66 and agrees very well with 
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previously reported correlations for individual compounds. As such, this experiment confirms 
general basic medicinal chemistry principles. However, there are also a number of exceptions 
to the general logDCsolubility rule. We here presented three statistically very well supported 
exceptions as examples, and many more can be found in the GRD. With MMPACbased rule 
databases such as the GRD, medicinal chemists can easily access and use all the “exception” 
rules in prospective design. 
We also showed that clearance is correlated to logD in transformation space, although the 
correlation is much weaker (R
2
 = 0.3 – 0.5). Clearance is a topic particularly well suited to 
MMPA, since beyond simple logD and exposure rules, principles to address clearance are 
almost exclusively based on rules about fragments and their relative stability. Here, we 
present only three rules that go counter to the accepted logD correlation. The supporting 
information contains some more rules, but the most natural way to access all the rules is 
through MMPACbased rule databases, since there are so many rules that it is impractical to 
print them all in a traditional article. With our big dataset, novel and interesting analyses 
about the correlations between species and microsomal and hepatocyte clearance can be 
made, all of which are however beyond the scope of this contribution. 
As a third example, we present the analysis of the correlation between logD and PPB in 
transformation space. We find that the two are highly correlated, if changes in the number of 
anions (mostly acids) are discarded. This is an important finding: it means that in the cases 
where free fraction is very hard to measure, a first estimate can be made using a matched pair 
measurement of logD and the correlation between delta logD and delta log free fraction. 
MMPA was critical in establishing this relationship as normal plots of free fraction versus 
logD are often compromised by the noise generated by very high or low free fraction values 
and the limit of PPB detection.  The real relationship between changes in logD and free 
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fraction could only be revealed thanks to the size of the datasets and the number of rules in 
GRD. 
Relationships between rules are also important and have been explored in the related  
matched molecular series studies.
38
 With a growing body of wellCdefined rules across 
different properties available for the common transformations, it is possible to create 
functional group scorecards, such as shown above for phenyl ClC and NCsubstitution (Tables 6 
and 7). These scorecards enable a quick overview of functional group properties (relative to a 
joint standard) and inform the choice of functional group substitution for property 
optimization. Those can form the basis of analysis across the medicinal chemistry knowledge 
space that may allow induction of AC rules from the known relationships of A→B and 
B→C. The recent work of Kramer
10
 suggests that this may be possible though the 
contributing transformations need to be very well exemplified to avoid the amplification of 
experimental error when combining rules. Larger datasets than the one considered here may 
be needed to enable these enhancements. 
Finally, such a corpus of knowledge may be used for the training of medicinal chemists.  
Historically medicinal chemists have learnt though their work on projects predominantly 
experientially, a time consuming and potentially unreliable route to gaining expertise.
39
 With 
the possibility of encoding medicinal chemistry knowledge in a consistent, robust, data dense, 
sharable manner, there is an opportunity to accelerate and enhance medicinal chemists’ skills.  
Access to a reference guide to what outcomes are “reasonable” for a given chemical change 
can allow chemists to set proposed compounds within the context of precedents and rank 
compounds in both synthetic tractability and probability of making the desired ADMET 
change. 
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-,.
We have demonstrated that significant knowledge can be extracted from large scale, 
unsupervised mining of in vitro ADMET data from multiple pharmaceutical companies.  
Within the organizations collaborating in this work and in those who have been able to 
exploit the data in trial form in universities and not for profit organizations, the knowledge 
has contributed to solving a number of drug hunting project problems leading to several 
publications .
40–42
 We have also shown examples of transformations that run counter to 
established wisdom. These may be useful tools to extricate a drug hunting team from a tight 
optimization corner and more generally to provide opportunities to enhance our 
understanding of the general SAR of the system being studied. Both of these are highly 
desirable goals. 
It is conceivable that the ensemble of rules found through MMPA on large datasets (as 
large as the one studied here or even larger) could form the basis for a statisticsCbased 
reference for medicinal chemistry, an “encyclopedia of medicinal chemistry tactics”.
37
 In this 
case, it matters less that the underlying pairs have not all been measured at the same place. 
What is really important is to maximize the size of dataset to broaden the resulting corpus of 
rules and the statistical meaningfulness. For PPB, we obtained promising results in an  
analysis based on the partitioning by environment and ion class.  Further partitions by factors 
such as shape or electronic descriptors could also be considered, though a clear mechanistic 
rationale justifying every partition is necessary as the analysis could fall into the traps of 
“data dredging” and generate false rules from statistical artifacts. 
Peter Norvig, a director of research at Google has published on the “Unreasonable 
Effectiveness of Data”,
43
 the concept that with a very large quantity of data, useful 
knowledge can be extracted in the absence of an underlying mechanistic model. For simple in 
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vitro ADMET properties it seems reasonable to suggest that we may be approaching this 
point in medicinal chemistry. It is possible to view the “brute force engineering” approach of 
data mining as inelegant to those more persuaded by a reductionistCtheoretical approach to 
compound optimization, however we see these two approaches as being on a continuum. 
Established theories are often built on a modest amount of experimental data, whereas data 
mining transformations brings a vast depth of data with no mechanistic model beyond the 
“fundamental belief” of chemistry that “structure defines properties”. The opportunity to 
enhance our SAR theories for ADMET properties by using the learning from data mining is 
an area as yet underCdeveloped and has the possibility of further accelerating drug hunting. 
As researchers at Pfizer have described it, this is the process of generating tacit knowledge 
from large datasets.
44
 Both the reductionistCtheoretical and pragmatic data mining approaches 
should accelerate lead optimization. Given that the urgent and essential goal of drug 
discovery is to deliver safe effective compounds to the clinic, and the continuing decrease in 
drug hunting productivity
45
 the simple truth is that medicinal chemists must increasingly look 
to more efficient practices and reliance on robust predictions and substantiated rules. 
%$ 
The supporting information contains the following information: 
 Additional detail and diagrams showing the capture of the local chemical 
environment round a point of change in a transformation 
 The data merging approach 
 Flowchart showing the method for assigning rules as significant 
 Solubility vs logD plots and confusion tables 
 72 additional rules in SMIRKS and drawn transformations 
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 Comparison to 7 previously published rules 
 Single company vs GRD comparison confusion tables. 
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AstraZeneca: Attilla.Ting@AstraZeneca.com +44 1625 234706 
Genentech  zheng.hao@gene.com +1 650 467 7446 
MedChemica ed.griffen@medchemica.com +44 1625 238843 
Roche  christian.kramer@roche.com +41 61 6822471 
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(0
:  
GRD  Grand Rule Database 
hERG human etherCaCgoCgo related gene product 
MMP Matched Molecular Pair 
MMPA Matched Molecular Pair Analysis 
MDCK cells Madin Darby Canine Kidney cells 
.#

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Sharing large quantities of knowledge across multiple large organizations is a rare 
occurrence in the pharmaceutical industry and would only have been possible by the support 
of a large technical team behind the scientists directly involved. At Genentech, Ying Littman 
and Slaton Lipscomb provided vital technical support and Ignacio Aliagas, Alberto Gobbi, 
Fabio Broccatelli, Jason Burch are thanked for many good discussions.  We are also thankful 
to Steve StCGallay and John Cumming for their assistance during the early stages of the 
collaboration.  The support of the Openeye technical staff and Anthony Nicholls was highly 
valuable in delivering the cheminformatics aspects of the collaboration. The scale of the 
knowledge sharing undertaken would not have been possible without the support of key 
leaders within the businesses concerned and their role in enabling such an undertaking is 
gratefully acknowledged. In particular MedChemica is grateful to Andy Barker and Phil 
Jewsbury for support at the genesis of this work, and Mike Snowden, Susan Galbraith, Mene 
Pangalos and Luca Santarelli for helping prosecute the first phase of data sharing. 
*
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Christian received his PhD from the University of Erlangen, Germany, working on the 
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In 2010, he moved to Basel, Switzerland, as a Novartis Presidential PostDoc, and in 2013 he 
accepted an assistant professorship position for Theoretical/ Computational chemistry at the 
University of Innsbruck, Austria. In 2015, he moved to F. HoffmannCLa Roche Ltd., where 
he works on therapeutic projects in multiple disease areas and develops computational 
methods. Christian’s research interests lie in the field of computerCaided drug design, trying 
to map and support the complex rationalization and decision processes that underlie 
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medicinal chemistry. This includes techniques such as QSAR, QSPR, matchedCmolecular 
pair analysis, data mining, and the analysis of experimental uncertainty. 
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Attilla Ting is a Computational Chemist and a project manager working with the 
Oncology Innovative Medicines drug discovery unit at AstraZeneca. Attilla’s responsibilities 
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along with project management responsibility. Attilla has a particular interest in structureC 
based drug design and automatic matched pair analysis. Attilla has published a number of 
papers in the drug discovery field. Attilla was awarded an Undergraduate degree in 
Chemistry and Computer science from The University of Leeds and continued into 
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Chemistry with Dr Peter Johnson before joining AstraZeneca in 2000. 
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Hao Zheng is an Associate Scientist at Genentech, where he has worked for the last 11 
years as a cheminformatics project manager and computational chemist in computational 
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workflow and provides computational modelling support to small molecule therapeutic 
projects. Hao has a particular interest in applying machine learning and predictive analytics in 
drug discovery. Hao holds a Masters degree in organic chemistry from Nanjing University 
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Marie Curie Fellow in the laboratories of Brian Shoichet at UCSF, and of Didier Rognan at 
the University of Strasbourg. He joined F. HoffmannCLa Roche in 2009 and initially worked 
on therapeutic projects in multiple disease areas. In 2013, he was appointed Head of the 
ComputerCAided Drug Design section. A member of the Chemical Biology Leadership Team, 
he is responsible for the coordination of cheminformatics and molecular design contributions. 
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30 scientific articles and patents. 
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